First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal for immunotherapy of cancer 2020-06, Vol.8 (1), p.e000222
Hauptverfasser: Hong, David S, Parikh, Aparna, Shapiro, Geoffrey I, Varga, Andrea, Naing, Aung, Meric-Bernstam, Funda, Ataman, Özlem, Reyderman, Larisa, Binder, Terri A, Ren, Min, Liu, Mingjie, Dayal, Satish, Siu, Amy Y, Sachdev, Pallavi, Xu, Lucy, Bhagawati-Prasad, Vijay, Tchakov, Ilian, Ooi, Chean Eng, Bao, Xingfeng, Marabelle, Aurelien
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page e000222
container_title Journal for immunotherapy of cancer
container_volume 8
creator Hong, David S
Parikh, Aparna
Shapiro, Geoffrey I
Varga, Andrea
Naing, Aung
Meric-Bernstam, Funda
Ataman, Özlem
Reyderman, Larisa
Binder, Terri A
Ren, Min
Liu, Mingjie
Dayal, Satish
Siu, Amy Y
Sachdev, Pallavi
Xu, Lucy
Bhagawati-Prasad, Vijay
Tchakov, Ilian
Ooi, Chean Eng
Bao, Xingfeng
Marabelle, Aurelien
description
doi_str_mv 10.1136/jitc-2019-000222
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1136_jitc_2019_000222</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1136_jitc_2019_000222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-afd1559055748a1cb53e41a43ef0c6ec70a96bdc06ef8bc4b803ec48d4f042733</originalsourceid><addsrcrecordid>eNpNkDtPwzAURi0EElXpznhHkGq4fuTREVVpqVSJDjBHjuNQV81DtgPKX-BXk6gMTN83HJ3hEHLP8IkxET-fbNCUI1tRROScX5EZx4hRJnl8_e_fkoX3p5FhKESapjPys7HOB2obeuxr1UB3VN7ADnzoywHaCmxd901bt2V_VqF1A2QJyngJI6uaoD7bxvowgYdtBhyoM9p0IwgZDUNnQMJDdpCPS7CjXAVrmuDh24YjqPJLNdqUoKdx_o7cVOrszeJv5-Rjk72vX-n-bbtbv-yp5lIEqqqSRdEKoyiRqWK6iISRTElhKtSx0QmqVVyUGmNTpYWWRYrCaJmWskLJEyHmBC9e7VrvnanyztlauSFnmE858ylnPuXMLznFL48UaDk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers</title><source>BMJ Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Hong, David S ; Parikh, Aparna ; Shapiro, Geoffrey I ; Varga, Andrea ; Naing, Aung ; Meric-Bernstam, Funda ; Ataman, Özlem ; Reyderman, Larisa ; Binder, Terri A ; Ren, Min ; Liu, Mingjie ; Dayal, Satish ; Siu, Amy Y ; Sachdev, Pallavi ; Xu, Lucy ; Bhagawati-Prasad, Vijay ; Tchakov, Ilian ; Ooi, Chean Eng ; Bao, Xingfeng ; Marabelle, Aurelien</creator><creatorcontrib>Hong, David S ; Parikh, Aparna ; Shapiro, Geoffrey I ; Varga, Andrea ; Naing, Aung ; Meric-Bernstam, Funda ; Ataman, Özlem ; Reyderman, Larisa ; Binder, Terri A ; Ren, Min ; Liu, Mingjie ; Dayal, Satish ; Siu, Amy Y ; Sachdev, Pallavi ; Xu, Lucy ; Bhagawati-Prasad, Vijay ; Tchakov, Ilian ; Ooi, Chean Eng ; Bao, Xingfeng ; Marabelle, Aurelien</creatorcontrib><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1136/jitc-2019-000222</identifier><language>eng</language><ispartof>Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000222</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c243t-afd1559055748a1cb53e41a43ef0c6ec70a96bdc06ef8bc4b803ec48d4f042733</citedby><cites>FETCH-LOGICAL-c243t-afd1559055748a1cb53e41a43ef0c6ec70a96bdc06ef8bc4b803ec48d4f042733</cites><orcidid>0000-0002-4803-8513 ; 0000-0002-5816-3019</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Hong, David S</creatorcontrib><creatorcontrib>Parikh, Aparna</creatorcontrib><creatorcontrib>Shapiro, Geoffrey I</creatorcontrib><creatorcontrib>Varga, Andrea</creatorcontrib><creatorcontrib>Naing, Aung</creatorcontrib><creatorcontrib>Meric-Bernstam, Funda</creatorcontrib><creatorcontrib>Ataman, Özlem</creatorcontrib><creatorcontrib>Reyderman, Larisa</creatorcontrib><creatorcontrib>Binder, Terri A</creatorcontrib><creatorcontrib>Ren, Min</creatorcontrib><creatorcontrib>Liu, Mingjie</creatorcontrib><creatorcontrib>Dayal, Satish</creatorcontrib><creatorcontrib>Siu, Amy Y</creatorcontrib><creatorcontrib>Sachdev, Pallavi</creatorcontrib><creatorcontrib>Xu, Lucy</creatorcontrib><creatorcontrib>Bhagawati-Prasad, Vijay</creatorcontrib><creatorcontrib>Tchakov, Ilian</creatorcontrib><creatorcontrib>Ooi, Chean Eng</creatorcontrib><creatorcontrib>Bao, Xingfeng</creatorcontrib><creatorcontrib>Marabelle, Aurelien</creatorcontrib><title>First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers</title><title>Journal for immunotherapy of cancer</title><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpNkDtPwzAURi0EElXpznhHkGq4fuTREVVpqVSJDjBHjuNQV81DtgPKX-BXk6gMTN83HJ3hEHLP8IkxET-fbNCUI1tRROScX5EZx4hRJnl8_e_fkoX3p5FhKESapjPys7HOB2obeuxr1UB3VN7ADnzoywHaCmxd901bt2V_VqF1A2QJyngJI6uaoD7bxvowgYdtBhyoM9p0IwgZDUNnQMJDdpCPS7CjXAVrmuDh24YjqPJLNdqUoKdx_o7cVOrszeJv5-Rjk72vX-n-bbtbv-yp5lIEqqqSRdEKoyiRqWK6iISRTElhKtSx0QmqVVyUGmNTpYWWRYrCaJmWskLJEyHmBC9e7VrvnanyztlauSFnmE858ylnPuXMLznFL48UaDk</recordid><startdate>20200617</startdate><enddate>20200617</enddate><creator>Hong, David S</creator><creator>Parikh, Aparna</creator><creator>Shapiro, Geoffrey I</creator><creator>Varga, Andrea</creator><creator>Naing, Aung</creator><creator>Meric-Bernstam, Funda</creator><creator>Ataman, Özlem</creator><creator>Reyderman, Larisa</creator><creator>Binder, Terri A</creator><creator>Ren, Min</creator><creator>Liu, Mingjie</creator><creator>Dayal, Satish</creator><creator>Siu, Amy Y</creator><creator>Sachdev, Pallavi</creator><creator>Xu, Lucy</creator><creator>Bhagawati-Prasad, Vijay</creator><creator>Tchakov, Ilian</creator><creator>Ooi, Chean Eng</creator><creator>Bao, Xingfeng</creator><creator>Marabelle, Aurelien</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-4803-8513</orcidid><orcidid>https://orcid.org/0000-0002-5816-3019</orcidid></search><sort><creationdate>20200617</creationdate><title>First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers</title><author>Hong, David S ; Parikh, Aparna ; Shapiro, Geoffrey I ; Varga, Andrea ; Naing, Aung ; Meric-Bernstam, Funda ; Ataman, Özlem ; Reyderman, Larisa ; Binder, Terri A ; Ren, Min ; Liu, Mingjie ; Dayal, Satish ; Siu, Amy Y ; Sachdev, Pallavi ; Xu, Lucy ; Bhagawati-Prasad, Vijay ; Tchakov, Ilian ; Ooi, Chean Eng ; Bao, Xingfeng ; Marabelle, Aurelien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-afd1559055748a1cb53e41a43ef0c6ec70a96bdc06ef8bc4b803ec48d4f042733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hong, David S</creatorcontrib><creatorcontrib>Parikh, Aparna</creatorcontrib><creatorcontrib>Shapiro, Geoffrey I</creatorcontrib><creatorcontrib>Varga, Andrea</creatorcontrib><creatorcontrib>Naing, Aung</creatorcontrib><creatorcontrib>Meric-Bernstam, Funda</creatorcontrib><creatorcontrib>Ataman, Özlem</creatorcontrib><creatorcontrib>Reyderman, Larisa</creatorcontrib><creatorcontrib>Binder, Terri A</creatorcontrib><creatorcontrib>Ren, Min</creatorcontrib><creatorcontrib>Liu, Mingjie</creatorcontrib><creatorcontrib>Dayal, Satish</creatorcontrib><creatorcontrib>Siu, Amy Y</creatorcontrib><creatorcontrib>Sachdev, Pallavi</creatorcontrib><creatorcontrib>Xu, Lucy</creatorcontrib><creatorcontrib>Bhagawati-Prasad, Vijay</creatorcontrib><creatorcontrib>Tchakov, Ilian</creatorcontrib><creatorcontrib>Ooi, Chean Eng</creatorcontrib><creatorcontrib>Bao, Xingfeng</creatorcontrib><creatorcontrib>Marabelle, Aurelien</creatorcontrib><collection>CrossRef</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hong, David S</au><au>Parikh, Aparna</au><au>Shapiro, Geoffrey I</au><au>Varga, Andrea</au><au>Naing, Aung</au><au>Meric-Bernstam, Funda</au><au>Ataman, Özlem</au><au>Reyderman, Larisa</au><au>Binder, Terri A</au><au>Ren, Min</au><au>Liu, Mingjie</au><au>Dayal, Satish</au><au>Siu, Amy Y</au><au>Sachdev, Pallavi</au><au>Xu, Lucy</au><au>Bhagawati-Prasad, Vijay</au><au>Tchakov, Ilian</au><au>Ooi, Chean Eng</au><au>Bao, Xingfeng</au><au>Marabelle, Aurelien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><date>2020-06-17</date><risdate>2020</risdate><volume>8</volume><issue>1</issue><spage>e000222</spage><pages>e000222-</pages><issn>2051-1426</issn><eissn>2051-1426</eissn><doi>10.1136/jitc-2019-000222</doi><orcidid>https://orcid.org/0000-0002-4803-8513</orcidid><orcidid>https://orcid.org/0000-0002-5816-3019</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2051-1426
ispartof Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000222
issn 2051-1426
2051-1426
language eng
recordid cdi_crossref_primary_10_1136_jitc_2019_000222
source BMJ Open Access Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
title First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2 -receptor E-type 4 (EP4), in patients with advanced cancers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T10%3A38%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-in-human%20phase%20I%20study%20of%20immunomodulatory%20E7046,%20an%20antagonist%20of%20PGE%202%20-receptor%20E-type%204%20(EP4),%20in%20patients%20with%20advanced%20cancers&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Hong,%20David%20S&rft.date=2020-06-17&rft.volume=8&rft.issue=1&rft.spage=e000222&rft.pages=e000222-&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1136/jitc-2019-000222&rft_dat=%3Ccrossref%3E10_1136_jitc_2019_000222%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true